Advera Health Analytics Adds Booz Allen Social Media Data and Analysis to its Evidex Drug Safety Analytics Platform

Share Article

Health Vigilance Data Derived from Publicly-Accessible Online Conversations will Provide Unparalleled Insight into Post-Approval Drug Safety Issues.

Advera Health Analytics, Inc., a global leader in pharmacovigilance software, analytics, and data at the leading edge of drug safety science, and Booz Allen Hamilton (NYSE:BAH), a global management and technology consulting firm, today announced a new partnership that will provide Advera’s clients with access to Booz Allen’s health vigilance data that examines publicly-available social media for adverse drug side effects within Advera’s Evidex drug safety analytics platform. This partnership is key to identifying adverse events earlier, enabling the medical community to take action sooner.

Booz Allen’s social media data and analytic capability observes and classifies online discussions of drug side effects. Public data collected from social media platforms are processed with an extensive library of natural language processing and machine learning tools that are tailored to the health domain. These automated aggregation processes are combined with manual curation to detect potential safety issues. In 2014, Booz Allen acquired Epidemico, Inc. which was working with regulatory agencies such as FDA and EMA, as well as pharmaceutical safety and epidemiology teams for early signal detection and hypothesis generation regarding both labeled and unlabeled safety events. The group has continued to invest and work in this area, coupling traditional consulting services with innovative tools and technology.

Advera Health’s Evidex data aggregation platform is a scalable, flexible, and agile way for pharmacovigilance professionals in the healthcare industry to access and analyze drug safety data. Powered by Advera’s proprietary RxFilter data optimization technology, Evidex supports a broad array of safety signal detection, signal management and risk mitigation use cases.

“We’re very excited to include Booz Allen Hamilton’s data in Evidex,” said Brian M. Overstreet, president & CEO of Advera Health Analytics. “Social media monitoring for drug safety issues is no longer just an emerging area of importance for pharmacovigilance professionals, but one that is required by regulatory agencies. Epidemico, now Booz Allen, has been a pioneer in this space, offering subject matter expertise, human data curation, and validated tools that will provide our clients the best possible solution. This partnership brings us one step further toward our vision of Pharmacovigilance 2.0 – the next generation of signal detection, management and mitigation from multiple real-world data sources.”

Chi Bahk, Epidemico Operations Lead at Booz Allen said, “This partnership expands the use of Booz Allen’s data further into the pharmacovigilance and drug safety space. We’re excited to partner with Advera Health to help their clients analyze social media data alongside Advera’s proprietary clinical trials safety outcomes data, their optimized spontaneous reported data from FDA’s Adverse Event Reporting System (FAERS) and Vigibase to better detect, manage, and evaluate emerging drug side effect risks directly within the Evidex platform. We believe this partnership will add a needed level of new insight into the post-approval drug safety industry.”

Epidemico is a Booz Allen tool used to identify and understand health topics derived from publicly-available online conversations across media sources, offering custom portfolios by topic. The scanning of public, social posts about drugs automates data collection from over 200,000 online sources to offer insights into drug-related conversations online.

Evidex’s integration of Booz Allen’s data allows for active monitoring of public social media posts for product side effects alongside clinical trial results, spontaneous reporting, and other real-world data. The data is fully mapped to all existing Evidex data to facilitate early signal detection and hypothesis generation.

For those interested in learning more, Advera Health has set up an information and inquiry web site specifically for the Booz Allen’s Epidemico Data:

About Advera Health Analytics
Advera Health Analytics is a global leader in pharmacovigilance software, analytics, and data at the leading edge of drug safety science. Founded in 2010 by a group of passionate healthcare entrepreneurs, Advera Health’s mission is to mitigate risk in the healthcare system by improving the transparency and actionability of drug safety data through the curation and aggregation of large disparate datasets and the application of proprietary analytics. Please visit as well as our newsroom, blog, Twitter, and LinkedIn pages for more information about the company.

About Evidex®
Advera Health’s Evidex® is a drug safety data aggregation platform that makes disparate drug safety data actionable though a simple to use yet powerful web-based application, empowering use at all organizational levels. Evidex is the gold standard resource for drug safety knowledge and insight, generated through proprietary curated data and analytics and powerful data integrations, enabling previously unavailable in-depth, rigorous adverse event analysis.

About Booz Allen
Booz Allen Hamilton (NYSE: BAH) has been at the forefront of strategy and technology for more than one hundred years. Today, the firm provides management and technology consulting and engineering services to leading Fortune 500 corporations, governments, and not-for-profits across the globe. Booz Allen partners with public and private sector clients to solve their most difficult challenges through a combination of consulting, analytics, mission operations, technology, systems delivery, cybersecurity, engineering and innovation expertise.

With international headquarters in McLean, Virginia, the firm employs approximately 24,225 people globally, and had revenue of $5.80 billion for the 12 months ended March 31, 2017. To learn more, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brian Overstreet
Follow >
Visit website